These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32673439)

  • 1. Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.
    Oldham M; Conrey A; Pittman C; Fisher C; Hargrett S; West K; Jackson M; Martin S; Hsieh MM; Jeffries N; Kaplarevic M; Johnson D; Olkhanud P; Fitzhugh CD
    J Clin Pharmacol; 2021 Jan; 61(1):41-51. PubMed ID: 32673439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
    Fitzhugh CD; Hsieh MM; Allen D; Coles WA; Seamon C; Ring M; Zhao X; Minniti CP; Rodgers GP; Schechter AN; Tisdale JF; Taylor JG
    PLoS One; 2015; 10(11):e0141706. PubMed ID: 26576059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease.
    Ogu UO; Mukhopadhyay A; Patel K; Nelson MN; Strahan KS; Wu L; Smeltzer MP; Ataga KI
    Eur J Haematol; 2024 Mar; 112(3):466-474. PubMed ID: 38019026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
    Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
    Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of hydroxyurea in the management of sickle cell disease.
    Davies SC; Gilmore A
    Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.